MannKind Keeps the Faith in Inhaled Insulin with Opening of $114 Million Production Plant in Connecticut

SUGAR LAND--September 17, 2008--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The MannKind Corporation (NASDAQ:MNKD) (Valencia, California) will unveil its new $114 million insulin system production plant in Danbury, Connecticut, today. Construction began last year on the project, which will produce, package and distribute the company's Technosphere insulin and inhaler. Earlier this year, Eli Lilly & Company (NYSE:LLY) (Indianapolis, Indiana), Novo Nordisk (NYSE:NVO) (Bagsvaerd, Denmark) and Pfizer Incorporated (NYSE:PFE) (New York, New York) all abandoned similar products that were designed to replace injections for those suffering from diabetes. MannKind, founded in 1991 by billionaire Alfred Mann, has firmly stayed the course with its development of the controversial product.